|  |
| --- |
| Declaration of Interests Register |
| TA Committee B Publication Date: 25/11/2020 |
| Topic: Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer [ID1443]  |
| Name | Role with NICE | Type of interest | Description of interest | Interestarose | Interestdeclared | Interest ceased | Comments  |
| Peter Wheatley-Price | TAC B Committee Member | Direct – financial  | Employed by Takeda who manufacture potential competitor products. | NA | 19/08/2020 | NA | It was agreed that this declaration would prevent Mr Wheatley-Price from participating in this section of the meeting. |
| Professor Amit Bahl | Clinical Expert | Direct – financial | Advisory boards and other meetings for Bayer and comparator companies including Sanofi, Astellas, BMS, Janssen, Pfizer, EUSA | NA | 30/01/2020 | NA | It was agreed that this declaration would not prevent Professor Bahl from participating in this section of the meeting. |
| Professor Heather Payne | Clinical Expert | Direct – financial | Received honorarium for presenting data in 2 scientific prostate cancer meetings sponsored by Bayer. The topics did not include this medication. | NA | 30/01/2020 | NA | It was agreed that this declaration would not prevent Professor Payne from participating in this section of the meeting. |
| Dr Stephen Allen | Patient Expert | Indirect -professional financial interest | His organisation, Tackle Prostate Cancer, receive unrestricted medical grants from several pharmaceutical companies. However, they have not received funding from a company that manufactures darolutamide in the previous twelve months. | NA | 09/09/2020 | NA | It was agreed that this declaration would not prevent Dr Allen from participating in this section of the meeting. |
| Dr Stephen Allen | Patient Expert | Direct - financial | One payment of expenses by Janssen to support attending a patient-centred meeting in Europe. This did not involve any commercial interests. | NA | 12/05/2020 | NA | It was agreed that this declaration would not prevent Dr Allen from participating in this section of the meeting. |
| Meg Burgess | Patient Expert | Indirect -professional financial interest | Her organisation, Prostate Cancer UK, received funding from pharmaceutical companies, including Bayer in the last twelve months. | NA | 03/09/2020 | NA | It was agreed that this declaration would not prevent Ms Burgess from participating in this section of the meeting. |